Find information on thousands of medical conditions and prescription drugs.

LCHAD deficiency

Long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency, often shortened to LCHAD deficiency is a rare genetic disorder that prevents the body from converting certain fats to energy, particularly during periods of fasting. This condition is inherited in an autosomal recessive pattern. more...

Home
Diseases
A
B
C
D
E
F
G
H
I
J
K
L
Amyotrophic lateral...
Bardet-Biedl syndrome
Labyrinthitis
Lafora disease
Landau-Kleffner syndrome
Langer-Giedion syndrome
Laryngeal papillomatosis
Laryngomalacia
Lassa fever
LCHAD deficiency
Leber optic atrophy
Ledderhose disease
Legg-Calvé-Perthes syndrome
Legionellosis
Legionnaire's disease
Leiomyoma
Leiomyosarcoma
Leishmaniasis
Lemierre's syndrome
Lennox-Gastaut syndrome
Leprechaunism
Leprophobia
Leprosy
Leptospirosis
Lesch-Nyhan syndrome
Leukemia
Leukocyte adhesion...
Leukodystrophy
Leukomalacia
Leukoplakia
LGS
Li-Fraumeni syndrome
Lichen planus
Ligyrophobia
Limb-girdle muscular...
Limnophobia
Linonophobia
Lipodystrophy
Lipoid congenital adrenal...
Liposarcoma
Lissencephaly
Lissencephaly syndrome...
Listeriosis
Liticaphobia
Liver cirrhosis
Lobster hand
Locked-In syndrome
Loiasis
Long QT Syndrome
Long QT syndrome type 1
Long QT syndrome type 2
Long QT syndrome type 3
LSA
Lung cancer
Lupus erythematosus
Lyell's syndrome
Lygophobia
Lyme disease
Lymphangioleiomyomatosis
Lymphedema
Lymphoma
Lymphosarcoma
Lysinuric protein...
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Medicines

Mutations in the HADHA gene lead to inadequate levels of an enzyme called long-chain 3-hydroxyacyl-coenzyme A (CoA) dehydrogenase, which is part of a protein complex known as mitochondrial trifunctional protein. Long-chain fatty acids from food and body fat cannot be metabolized and processed without sufficient levels of this enzyme. As a result, these fatty acids are not converted to energy, which can lead to characteristic features of this disorder, such as lethargy and hypoglycemia. Long-chain fatty acids or partially metabolized fatty acids may build up in tissues and damage the liver, heart, retina, and muscles, causing more serious complications.

Typically, initial signs and symptoms of this disorder occur during infancy or early childhood and can include feeding difficulties, lethargy, hypoglycemia,hypotonia, liver problems, and abnormalities in the retina. Muscle pain, a breakdown of muscle tissue, and abnormalities in the nervous system that affect arms and legs (peripheral neuropathy) may occur later in childhood. There is also a risk for complications such as life-threatening heart and breathing problems, coma, and sudden unexpected death. Episodes of LCHAD deficiency can be triggered by periods of fasting or by illnesses such as viral infections.

Read more at Wikipedia.org


[List your site here Free!]


Management of fatty acid oxidation disorders - Genetic Disease and Nutrition
From Nutrition Research Newsletter, 1/1/03

Fatty acid oxidation disorders are defined by a defect in the fatty acid oxidation pathway. An inability to mobilize fatty acids for energy and a restriction in the breakdown of fats of specific lengths are hallmarks of these genetic disorders. Standard treatment of fatty acid oxidation disorders is by way of medical nutrition therapy. However, fatty acid oxidation disorders encompass a large and diverse number of disorders and treatment and management pose a unique challenge to metabolic dietitians.

With an increasing number of affected individuals being identified, it is essential that nutrition intervention be initiated as soon as a diagnosis is established. A recent study by two researchers from Emory University surveyed metabolic dietitians across the United States to determine nutritional strategies currently employed for the treatment of fatty acid oxidation disorders.

A survey was sent to all members of the PNO-METAB-L listserv, which includes metabolic dietitians throughout the United States. Questions were asked regarding nutrient composition of total diet, use of specialized formulas or lipid preparations including dose and frequency and parameters used to monitor dietary management and disease progression. The same questions were asked for each of three disease categories: medium-chain Acyl-CoA dehydrogenase deficiency (MCAD); very-long-chain Acyl-CoA dehydrogenase deficiency (VLCAD); and a third category that combined long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHAD), long-chain Acyl-CoA dehydrogenase deficiency (LCAD) and trifunctional protein deficiency (TFP).

Forty-nine dietitians returned the survey. Twenty-five reported no patients in their practice with fatty acid oxidation disorders and 24 reported interaction with current or past patients with these disorders. The 24 informative respondents represented information regarding 200 individual patients with fatty acid oxidation disorders including 114 patients with MCAD, 26 with VLCAD, 23 with LCHAD or TFP and 37 patients in the `other' category. All 24 dietitians reported prescribing an increased frequency of meals. Fourteen dietitians reported prescribing cornstarch, with the highest use in patients with LCHAD and TFP. Cornstarch is administered to minimize fasting intolerance in affected individuals, especially during sleeping hours or before intense activity. Twenty respondents prescribed carnitine as a supplement; the majority of carnitine usage was in patients with MCAD, LCHAD and TFP with the median dose being 75 mg/kg/day. Twenty-two dietitians reported restricting fat intake of patients with these disorders. The median fat restriction was 29% of the diet, with a range of 10 to 35%. Fourteen of the respondents reported prescribing medical formulas to provide a diet low in fat and yet dense in all other nutrients, while 16 reported supplementation with specific oils including flaxseed, canola, walnut, or safflower oil.

Current standard of care appears to focus on fat restriction and increased meal frequency with the increasing use of cornstarch and/or carnitine supplementation. The clinical efficacy of medium-chain triglyceride oil, other lipid substrates and medical foods requires further study for the development of standardized treatment and monitoring strategies and product formulations tailored to the needs of patients with fatty acid oxidation disorders.

Java O. Solis and Rani H. Singh, Management of fatty acid oxidation disorders: a survey of current treatment strategies, JADA 102(12): 1800-1806 (December 2002) [Address correspondence to: Rani H. Sing, Emory University, Department of Pediatrics, Division of Medical Genetics, 2040 Ridgewood Dr, NE, Atlanta, GA 30322. E-mail: rhs@rw.ped.emory.edu]

COPYRIGHT 2003 Frost & Sullivan
COPYRIGHT 2003 Gale Group

Return to LCHAD deficiency
Home Contact Resources Exchange Links ebay